Precision Biosciences Inc.
A clinical-stage gene editing company whose ARCUS platform, built on a naturally occurring enzyme first found in green algae, develops therapies for chronic hepatitis B and Duchenne muscular dystrophy. Three Duke University postdocs founded the company in 2006 after their lab discovery placed second in a university start-up challenge, and the earliest ARCUS work actually edited crops like corn and soybean before turning to human medicines.
Granted 882.7K · Sold 363.5K
Granted 158.2K · Sold 53.8K
Granted 367.1K · Bought 5.1K · Sold 39.5K
Granted 193.8K · Sold 61.9K
Granted 35.0K · Bought 13.9K
Granted 35.0K · Bought 9.9K
Granted 35.0K · Bought 9.3K
Granted 35.0K · Bought 5.4K
Granted 35.0K
Granted 61.9K · Sold 22.1K
Granted 4.2K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Amoroso MichaelPresident and CEO, Director · 21 transactions | +254.1% | 243.4K | 882.7K | — | 363.5K |
| Smith J. JeffersonChief Research Officer · 19 transactions | -94% | 129.9K | 158.2K | — | 53.8K |
| Kelly John AlexanderChief Financial Officer · 21 transactions | -67.2% | 125.9K | 367.1K | 5.1K | 39.5K |
| Scimeca DarioGeneral Counsel and Secretary · 24 transactions | -17.5% | 56.5K | 193.8K | — | 61.9K |
| Buehler KevinDirector · 6 transactions | +761.9% | 49.1K | 35.0K | 13.9K | — |
| Germano Geno JDirector · 6 transactions | — | 44.9K | 35.0K | 9.9K | — |
| Brown MelindaDirector · 8 transactions | — | 44.3K | 35.0K | 9.3K | — |
| Frankel StanleyDirector · 5 transactions | +2598.5% | 40.5K | 35.0K | 5.4K | — |
| Pire Shari LisaDirector · 3 transactions | — | 35.0K | 35.0K | — | — |
| List AlanChief Medical Officer · 6 transactions | -92.1% | 4.5Kas of May 2024 | 61.9K | — | 22.1K |
| Wadsworth Samuel C.Director · 1 transaction | — | 4.2Kas of May 2024 | 4.2K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 3 years: -497.1K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.